Tedizolid: a service evaluation in a large UK teaching hospital
- PDF / 267,711 Bytes
- 9 Pages / 595.276 x 790.866 pts Page_size
- 109 Downloads / 178 Views
BRIEF REPORT
Tedizolid: a service evaluation in a large UK teaching hospital Joshua A. York 1,2 & Kate Adams 1 & Lorraine Cullen 1 & Joanne Delahay 1 & Monica Ivan 1 & Patrick J. Lillie 1 & Laura MacLachlan 1 & Gavin Barlow 1,2 Received: 14 May 2020 / Accepted: 24 August 2020 # Springer-Verlag GmbH Germany, part of Springer Nature 2020
Abstract Tedizolid is a new oxazolidinone antibiotic with little real-life data on use outside of skin and soft tissue infections. There is a paucity of safety evidence in courses greater than 6 days. Our centre uses tedizolid predominantly when linezolid-associated adverse events have occurred. This service evaluation describes our experience to date. We performed a retrospective service evaluation by reviewing case notes, prescription charts, and laboratory system results for each patient prescribed tedizolid at our hospital and recording patient demographics, clinical details, and outcomes. Sixty patients received tedizolid between May 2016 and November 2018. Most were treated for bone or joint infections and had stopped linezolid prior to tedizolid prescription. Mean length of tedizolid therapy was 27 days. Haematological adverse effects were infrequent. Most patients (72%) finished the course and their clinical condition improved during treatment (72%). Adverse events were common, but often not thought to be tedizolid related. Tedizolid appears to be safe in prolonged courses within this context. It may be suitable for longer-term antibiotic therapy within a complex oral and parenteral outpatient antibiotic therapy (COPAT) service. Patients who do not tolerate linezolid can be safely switched to tedizolid if appropriate. Keywords Tedizolid . Oxazolidinone . Linezolid . Antibiotic . Stewardship
Introduction Tedizolid is a relatively new oxazolidinone antibiotic, active against Gram-positive bacteria, and licenced in the UK for the treatment of acute skin and associated structure bacterial infections (SASBIs). Tedizolid 200 mg once daily for 6 days was shown to be as efficacious as 10 days of linezolid (600 mg twice daily) in a randomised controlled trial [1]. The potential to extend tedizolid use to other indications, however, remains unclear due to lack of data [2]. Data are also needed to demonstrate tolerance compared with linezolid in courses longer than 6 days [2]. A recent series of four patients showed that it was possible to use it successfully for 7 to 14 days [3].
The potential for tedizolid to be used as a switch agent from linezolid in patients who have developed linezolid-associated adverse effects (LAAEs) has not been adequately investigated. Our centre has used tedizolid since 2016, mainly within the complex oral and parenteral antibiotic therapy (COPAT) service, to treat a range of infections other than SASBIs. Patients who have developed LAAEs have commonly been switched to tedizolid and prolonged therapy has been prescribed. Within our institution, tedizolid can only be prescribed by an infection consultant when oxazolidinone therapy is considered optimal wi
Data Loading...
